This study confirmed that a combination application of PSMA whole-body PET/CT and pelvic PET/MR can accurately distinguish BPH/prostatitis from prostate cancer and accurately stage prostate cancer. The gene discussed is FOLH1; the disease is benign prostatic hyperplasia.